BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

Battery Ventures to Take Private Enzo Biochem in All-Cash Transaction

August 28, 2025

Healthcare Services

Battery Ventures will acquire Enzo Biochem in an all-cash transaction for approximately $37 million, valuing Enzo at $0.70 per share. The deal was announced after Enzo’s board entered into an Agreement and Plan of Merger on June 23, 2025, and is expected to close in the third quarter of 2025 subject to customary closing conditions and shareholder approval.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Ipsen Acquires Epizyme to Expand Oncology Portfolio

August 12, 2022

Pharmaceuticals

Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.

Halozyme Acquires Antares Pharma for $960M

April 13, 2022

Pharmaceuticals

Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.

Arranta Bio Acquires Captozyme

November 13, 2019

Biotechnology

Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.